Oryzon Genomics (ISIN Code: ES0167733015, ORY), a public clinical-stage biopharmaceutical company leveraging epigenetics to develop therapies in diseases with strong unmet medical need, announced that the Company will present preliminary safety and efficacy clinical data of its investigational drug ORY-1001, a LSD1 selective inhibitor, at a poster session at the American Society of Hematology (ASH) 58th Annual Meeting and Exposition, being held December 3-6, 2016 in San Diego, California.
Investor / Analyst Luncheon
Oryzon will host an investor an d analyst luncheon on Monday, December 5, 2016 at at 12: 30 PM - 1: 30 PM PST at the San Diego Marriott Gaslamp Quarter Hotel. Management, investigators Tim Somervaille ( T h e Christie NHS Foundation Trust) and Francesc Bosch (University Hospital Vall d'Hebron ) , and Roche representative Gwen Nichols (Roche Translational Clinical Research Center) will discuss ORY - 1001 Phase I/IIA data in Acute Myeloid Leukemia. The luncheon will be webcast, and an archived version of the webcast will be available for replay follo wing the event and can be accessed on the Oryzn website.
The abstract is available on the official website of ASH - 2016 Conference https://ash.confex.com/ash/2016/webprogram/Paper93141.html
About ORY 1001
ORY - 1001 (RG6016), Oryzon’s first clinical asset, is a highly potent and selective Lysine Specific Demethylase - 1 (LSD1) inhibitor for the treatment of leukemia and other malignancies, currently in Phase I/IIA in Acute leukemia, that was partnered with Roche in a global deal in 2014. Beyond hematological malignancies, LSD1 inhibition has been proposed as a valid therapeutic approach in some solid tumors such as Small cell lung cancer (SCLC). SCLC represents 15% of lung neoplasms and is an aggressive malignancy with limited treatment options. Survival in refractory settings is typically less than one year, exemplifying the need for more effective therapeutics. Recent published results suggest that epigenetic modulation mediated by LSD1 inhi bition may be effective to treat SCLC.
Founded in 2000 in Barcelona, Spain, Oryzon (ISIN Code: ES0167733015) is a clinical stage biopharmaceutical company considered as the European champion in Epigenetics. The company has one of the stronge st portfolios in the field and a clinical asset already partnered with Roche. Oryzon’s LSD1 program is currently covered by + 20 patent families and has rendered two compounds in clinical trials. In addition, Oryzon has ongoing programs for developing inhib itors against other epigenetic targets. The company has a strong technological platform for biomarker identification and performs biomarker and target validation for a variety of malignant and neurodegenerative diseases. Oryzon’s strategy is to develop fir st in class compounds against novel epigenetic targets through Phase II clinical trials, at which point it is decided on a case - by - case basis to either keep the development in - house or to partner or outlicense the compound for late stage development and co mmercialization. The company has offices in Barcelona and Cambridge, Massachusetts. For more information, visit www.oryzon.com .